Abstract: Ergot alkaloids are pharmaceutically and agriculturally important secondary metabolites produced by several species of fungi. Ergot alkaloid pathways vary among different fungal lineages, but the pathway intermediate chanoclavine-I is evolutionarily conserved among ergot alkaloid producers. At least four genes, dmaW, easF, easE, and easC, are necessary for pathway steps prior to chanoclavine-I; however, the sufficiency of these genes for chanoclavine-I synthesis has not been established. A fragment of genomic DNA containing dmaW, easF, easE, and easC was amplified from the human-pathogenic, ergot alkaloid-producing fungus Aspergillus fumigatus and transformed into Aspergillus nidulans, a model fungus that does not contain any of the ergot alkaloid synthesis genes. HPLC and LC-MS analyses demonstrated that transformed A. nidulans strains produced chanoclavine-I and an earlier pathway intermediate. Aspergillus nidulans transformants containing dmaW, easF, and either easE or easC did not produce chanoclavine-I but did produce an early pathway intermediate and, in the case of the easC transformant, an additional ergot alkaloid-like compound. We conclude that dmaW, easF, easE, and easC are sufficient for the synthesis of chanoclavine-I in A. nidulans and expressing ergot alkaloid pathway genes in A. nidulans provides a novel approach to understanding the early steps in ergot alkaloid synthesis.
Introduction
Ergot alkaloids are tryptophan-derived mycotoxins produced by several different fungi and have proven to be both pharmaceutically and agriculturally important. Several Claviceps, Neotyphodium, and Epichloë species of the order Hypocreales produce a variety of complex ergot alkaloids [1, 2] . Aspergillus fumigatus and Penicillium commune of the order Eurotiales also are capable of ergot alkaloid synthesis; however, their ergot alkaloid profiles differ considerably from those of the Hypocrealean ergot alkaloid producers [2, 3] . Ergot alkaloid-producing fungi contain an ergot alkaloid synthesis (eas) gene cluster with a set of core genes that is well conserved [1] [2] [3] [4] . The eas clusters of the various ergot alkaloid producers also contain variable, lineage-specific genes that result in the formation of different pathway products among lineages [2, 4] . The steps of ergot alkaloid synthesis leading to the formation of chanoclavine-I (the earliest ergot alkaloid pathway biosynthetic intermediate observed accumulating in most producers) ( Figure 1 ) are believed to be evolutionarily conserved among the different fungi that produce ergot alkaloids [1] [2] [3] [4] ; however, the identity and catalytic activities of all the genes required for chanoclavine-I synthesis have not yet been determined. Based on the proposed biochemical scheme of Kozikowski et al. [5] , the synthesis of chanoclavine-I occurs in at least five steps. Gene knockout and heterologous expression studies have demonstrated that at least four genes, dmaW, easF, easE, and easC, are required prior to chanoclavine-I [6] [7] [8] [9] . However, it is currently unknown whether these genes are sufficient to synthesize chanoclavine-I. DMAT synthase, the product of dmaW, catalyzes the initial prenylation reaction to yield dimethylallyltryptophan (DMAT) [6, 10, 11] , and easF encodes a methyltransferase that N-methylates DMAT to form the second intermediate, N-Me-DMAT [7] . The order of activity and function of EasE and EasC have not been established, though gene knockout studies indicate these enzymes are necessary for the conversion of N-Me-DMAT to chanoclavine-I [8, 9] . Based on their sequences, easE encodes an oxidoreductase and easC encodes a catalase. Involvement of additional enzymes cannot be excluded because the synthesis of chanoclavine-I requires two two-electron oxidations, and EasE is the only oxidoreductase among the four required genes. However, the eas clusters in the diverse fungi that produce ergot alkaloids do not contain any additional conserved oxidoreductase genes for which a function has not been assigned. Thus, the question of sufficiency of the four required genes is unresolved.
Aspergillus fumigatus is a common saprophytic fungus and potentially fatal pathogen in immunocompromised individuals [12] . Ergot alkaloid synthesis genes are clustered in the A. fumigatus genome [10, 11] and are expressed during asexual reproduction [13, 14] . Aspergillus nidulans, a model fungus that is closely related to A. fumigatus, does not contain the ergot alkaloid gene cluster nor does it produce ergot alkaloids. The primary objective of this study was to test if dmaW, easF, easC, and easE are sufficient to direct chanoclavine-I synthesis in A. nidulans. We used a novel approach to test the sufficiency of the genes by transforming A. nidulans with dmaW, easF, easC, and easE, or subsets of those genes, from A. fumigatus under the control of their native promoters. 
Results

Engineering of Chanoclavine-I Producing
Engineering of A. nidulans Strains Expressing Subsets of Early Pathway Genes
Two additional mutant strains of A. nidulans were generated by transformation with subsets of three of the four ergot alkaloid cluster genes: strains WFC (containing dmaW, easF, and easC) and WFE (containing dmaW, easF, and easE). The presence of each gene in the genomes of the different mutants was verified by PCR ( Figure 2 ). Chanoclavine-I was not detectable by HPLC ( Figure 5 ) or ESI LC-MS (data not shown) in either strain. Expression of dmaW and easF from the inserted construct in both strains was validated by the accumulation of the early pathway intermediate, N-Me-DMAT, which eluted from the column at approximately 44 min ( Figure 5 ). In addition, WFC cultures accumulated a novel molecule with an elution time of 41 min and that had an m/z value of 259.0 in ESI LC-MS analyses. The unidentified metabolite displayed a higher fluorescence at excitation and emission wavelengths of 310 nm and 410 nm, respectively, than at 272 nm excitation and 372 nm emission settings ( Figure 5 ). Ergot alkaloids with a double bond between carbons 9 and 10 of the ergot alkaloid ring system fluoresce stronger at the 310 nm (excitation) and 410 nm (emission) setting compared to their fluorescence at the 272 nm/372 nm setting; conversely, ergot alkaloids with a 8,9 double bond or those lacking a double bond at either of those positions fluoresce stronger at the 272 nm/372 nm setting [15] . The novel alkaloid was not produced in sufficient quantities to allow the acquisition of additional structural data at this time. 
Discussion
Our results describe the first transfer of ergot alkaloid biosynthetic capability to a previously non-producing fungus. These data also indicate that dmaW, easF, easE, and easC are sufficient for A. nidulans to synthesize chanoclavine-I. Since the pathway leading to the formation of chanoclavine-I appears to be evolutionarily conserved, the knowledge gained from this study will not only apply to A. fumigatus but theoretically to all ergot alkaloid producers. Despite the large amount of research conducted on ergot alkaloid synthesis, the formation of chanoclavine-I has yet to be completely understood. Only two steps in this evolutionarily conserved portion of the pathway have been completely characterized-those controlled by dmaW and easF [6, 7, 10, 11] . After the formation of N-Me-DMAT, the order of activity and catalytic functions of enzymes is not clear. Our data indicate that EasE and EasC individually are necessary and together are sufficient to convert N-Me-DMAT to chanoclavine-I. Nonetheless, the observations in this study do not rule out the possibility that A. nidulans naturally possesses an enzyme that also contributes to the formation of chanoclavine-I from N-Me-DMAT. Despite the fact that all known ergot alkaloid genes are clustered in A. fumigatus and other ergot alkaloid-producing fungi [1] [2] [3] [4] 15] , we cannot presently exclude the possibility that a required gene in the pathway may be located elsewhere in the genome and common to non-producing fungi.
Transformations with subsets of three of the four studied genes, combining alternately easC or easE with the combination of dmaW and easF, did not yield strains capable of producing chanoclavine-I.
These results support previous knockout data indicating that both easE and easC are required for chanoclavine-I synthesis from N-Me-DMAT [9] . A metabolite of undetermined structure accumulated to relatively high levels in the WFC transformant; this metabolite was not detectable in extracts of the A. nidulans WFE strain. Improved strains or altered growth conditions will be necessary to increase yield of the compound for the purpose of collecting adequate material for structure determination. The WFC analyte could potentially be the next intermediate downstream of N-Me-DMAT, in which case easC would code for the enzyme involved in the third step of ergot alkaloid synthesis. Considering its catalase activity, one proposed function for EasC is detoxification of hydrogen peroxide produced from the oxidative activities of EasE [9] , in which case EasC would not act directly on an ergot alkaloid substrate; however, comparison of the alkaloid profiles of WFE and WFC mutants indicates that EasC can act independent of EasE and chemically modifies an ergot alkaloid substrate. In a previous study, easE was knocked out in A. fumigatus, creating a strain of A. fumigatus that lacked easE but contained easC [9] . N-Me-DMAT was detected in cultures of the easE knockout strain, but the novel metabolite from the A. nidulans WFC strain was not observed. One potential explanation for this apparent discrepancy is that the A. fumigatus easE knockout mutant contained downstream enzymes in the ergot alkaloid pathway that may have altered its ergot alkaloid profile. Alternatively, the difference between alkaloid profiles of A. fumigatus easE knockout and A. nidulans WFC could be due to other factors in the species backgrounds in which N-Me-DMAT accumulated. It is presently unknown whether the observed WFC analyte is an actual, on-pathway intermediate or whether it is a byproduct of EasC acting out of sequence on a compound that is not ordinarily its substrate. Feeding studies with the unidentified analyte and strains expressing defined sets of ergot alkaloid synthesis genes would be a reasonable approach to test the involvement of this compound in the ergot alkaloid pathway. Again, greater quantities of the analyte would be required for such studies. An in vitro approach involving separate and combined enzymes also would help to fully understand the functions of these enzymes. Difficulty with expressing EasE in active form in vitro has slowed studies of catalytic function of this enzyme [9] .
The approach of expressing genes in A. nidulans may be applied to other genes in the pathway to study their roles in the biosynthesis of ergot alkaloids (as was recently reviewed by Chiang et al. [16] for other fungal secondary metabolite pathways). Heterologous expression in A. nidulans also should be applicable to studying genes from ergot alkaloid pathways of other fungi, such as those genes from lineage-specific branches of the pathway. In such cases, it may be necessary to replace the native promoters of those heterologous genes with promoters from A. fumigatus eas genes or strong A. nidulans promoters.
Experimental Section
Fungal Strains and Growth Conditions
Aspergillus fumigatus isolate Af293, as a source of genomic DNA, was grown in malt extract broth (15 g malt extract/L) overnight at 37 °C. The uridine auxotrophic A. nidulans isolate FGSC A767 (Fungal Genetic Stock Center, Kansas City, MO, USA) was grown at 37 °C on SYE medium (20 g/L sucrose, 10 g/L yeast extract, 10 g/L MgSO 4 , 2 mL/L trace element solution [17] , 2.2 g/L uracil, 2.2 g/L uridine, with or without 15 g/L agar). For preparation of protoplasts, A. nidulans was grown in liquid SYE medium overnight. Transformants were regenerated on selective SYE agar medium which did not contain uracil or uridine and was supplemented with 304 g/L sucrose (to serve as osmoticum as well as carbon source). To test alkaloid accumulation, cultures were grown on SYE agar medium at 37 °C for one week.
DNA Manipulations
DNA was extracted from A. fumigatus according to the protocol described by Richards et al. [18] . An 8774-bp fragment containing dmaW, easF, easC, and easE was amplified by PCR primed with oligonucleotides primer 1 (5'-TACCTATACCTAATCGAAGCCGCACGCAGTGCACC-3') and primer 2 (5'-GCCGCCCATTCACCAAGATTTTTGCACAAATCTGCG-3'). A 25 μL reaction contained 1× LongAmp Taq reaction buffer, 200 μM of each deoxynucleotide triphosphate, 1 μM of each primer, and 2.5 units LongAmp Taq DNA polymerase (New England BioLabs, Ipswich, MA, USA). The reaction began with an initial denaturing step of 3 min at 94 °C, followed by 35 cycles of 30 s at 94 °C and 10 min at 65 °C, with a final extension of 5 min at 65 °C.
A 6123-bp fragment containing dmaW, easF, and easE was amplified by PCR primed with oligonucleotides primer 3 (5'-GAGAGCTACTTGACATATTGTGTCGGCAGGTGCGCA-3') and primer 2 (5'-GCCGCCCATTCACCAAGATTTTTGCACAAATCTGCG-3'). The PCR conditions were the same as stated above except the elongation time was 7 min.
In order to generate transformant WFC (containing dmaW, easF, and easC), two separate DNA fragments were amplified for co-transformation. The first fragment containing dmaW and easC was primed with primer 1 (5'-TACCTATACCTAATCGAAGCCGCACGCAGTGCACC-3') and primer 5 (5'-CTACTCCATTGTCCTGTGAGTTG-3') which primed amplification of a 4846-bp fragment. The PCR conditions were the same as stated above except the elongation time was 5 min. The second fragment (2943 bp) contained only easF and was amplified by PCR primed with oligonucleotides easFF (5'-TCCATTCTTCGCTCGTTCAACCAGCAGG-3') and easFR (5'-CAGGACCTGTACCT AAAGCCTGGTAACC-3') in a 25 μL reaction containing 1× GoTaq Flexi buffer, 200 μM each deoxynucleotide triphosphate, 1.5 mM MgCl 2 , 1 μM of each primer, and 2.5 units of Taq DNA polymerase (Promega, Madison, WI, USA). The reaction began with an initial denaturing step of 3 min at 94 °C, followed by 35 cycles of 30 s at 94 °C, 30 s at 55 °C, and 3 min at 72 °C, with a final extension of 5 min at 72 °C.
PCR products were purified with QIAquick gel extraction kits (Qiagen, Valencia, CA, USA) prior to their inclusion in fungal transformations. The selectable marker pPyrG was obtained from the Fungal Genetics Stock Center and was digested with XhoI (New England BioLabs, Ipswich, MA, USA) and purified with QIAquick gel extraction kit prior to transformation.
Fungal Transformation and Screening
Protoplasts of A. nidulans FGSC A767 were prepared by incubating overnight cultures with 50 mg driselase (Sigma-Aldrich, St. Louis, MO, USA), which was filter sterilized with a 0.22 μm filter, and 75 mg lysing enzyme (Sigma-Aldrich, St. Louis, MO, USA) in 15 mL of 0.7 M sodium chloride. Protoplasts were purified and co-transformed with PCR product and selectable marker (pPyrG) as described by Coyle et al. [19] . Protoplasts were plated on SYE agar medium containing no uracil or uridine. Transformation plates were incubated at 37 °C, and transformants were collected approximately three days after transformation.
Each transformant was screened by PCR for the presence or absence of dmaW, easF, easC, and easE. An internal region of dmaW was primed with dmaWF (5'-TTGATCTGGAGTGGTTCCGC-3') and dmaWR (5'-CGTTCATGCCGAAGGTTGTG-3') yielding a 651-bp fragment. Primers for amplifying an internal region of easE were easEF (5'-CCAGATACATTGCCATCGCATG-3') and easER (5'-TGTTCCAACTGCTTGGCCAGAT-3'), which primed amplification of a 897-bp fragment. The presence or absence of easC was tested by PCR with primers easCF (5'-GAATTCGAGGTATTGATCTCC-3') and easCR (5'-AGCCAGGCAAAGATCCATAGTT-3') which flank a 1036-bp fragment. An internal region of easF was primed with easFF (5'-AAGTTGTCGAAGGTCTCACGAA-3') and easFR (5'-GTGATTAGAGATGCTTCTGTC-3'), yielding an 820-bp fragment. Each of these PCRs were 25 μL reactions containing 1× GoTaq Flexi buffer, 200 μM deoxynucleotide triphosphate, 1.5 mM MgCl 2 , 1 μM of each primer, and 2.5 units of Taq DNA polymerase (Promega, Madison, WI, USA). PCR conditions began with an initial denaturing step of 3 min at 94 °C, followed by 35 cycles of 30 s at 94 °C followed by 30 s at 55 °C, and 1 min and 30 s at 72 °C, followed by a final extension of 5 min at 72 °C.
HPLC Analyses
Transformants positive for the presence of the target genes were analyzed by HPLC for the accumulation of chanoclavine-I. Ergot alkaloids were extracted by incubating a spore-rich sample of the colony, containing approximately 1 cm 2 of culture surface area, in 400 μL of methanol for 30 min and clarifying the extract by centrifugation. Extracts were injected into a C 18 column (Prodigy 5-μm ODS3 (150 mm by 4.6 mm); Phenomenex, Torrance, CA, USA) and subjected to a multilinear binary gradient from 5% (v/v) acetonitrile plus 95% (v/v) aqueous 50 mM ammonium acetate to 75% acetonitrile plus 25% aqueous 50 mM aqueous ammonium acetate at a flow rate 1 mL/min, as previously described [15] . Ergot alkaloids were detected using two fluorescence settings. The first setting had an excitation wavelength of 272 nm and emission wavelength of 372 nm; the second setting was 310 nm (excitation) and 410 nm (emission). Chanoclavine-I (generously provided by Brian Tapper, AgResearch, New Zealand) and N-Me-DMAT (gift from Sarah O'Connor, University of East Anglia) were run as standards. Peaks of interest were isolated from the HPLC by collecting the runoff from the discard tube for 30 s after the peak was visualized on the detector.
LC-MS Analyses
Ergot alkaloid extracts were prepared by washing the surface of a conidiating colony with 2 mL of methanol, rotating the extract at 30 rpm for 30 min, and then clarifying the extract by centrifugation. Clarified extracts were then concentrated to a volume of 50 μL in a speed-vac apparatus, and 10 μL of concentrated extract were injected into the LC-MS. To isolate individual analytes, concentrated extracts were analyzed by fluorescence HPLC, peaks were collected manually, and concentrated to a volume of 50 μL in a speed-vac apparatus prior to LC-MS analysis. Concentrated samples were analyzed on a Finnigan LCQDecaXP plus mass spectrometer equipped with a Surveyor HPLC system.
